CTSC and bronchiectasis: Positive results from the Phase II WILLOW study and Phase III ASPEN study demonstrate that compared to placebo controls, DPP1 inhibition treatment can significantly extend time intervals to first acute exacerbations in bronchiectasis patients and effectively reduce overall acute exacerbation occurrence frequency (Chalmers et al., 2020; Chalmers et al., 2025b).